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ABSTRACT  Huntingtonǯs disease (HD) is a severe neurodegenerative condition that impacts the 
whole family. Prenatal diagnosis by direct or exclusion testing is available for 
couples at risk of transmitting HD to their children. An ethical problem can arise 
after prenatal diagnosis for HD if a known Ǯhigh riskǯ pregnancy is continued to 
term: international guidelines emphasise that this situation should be avoided 
where possible, as it removes the resulting childǯs future right to make an informed, 
autonomous decision about predictive testing. The UK Huntingtonǯs Disease 
Predictive Testing Consortium recorded 21 pregnancies that were tested, identified 
as high-risk and then continued. In this qualitative study, health professionals 
reviewed the case notes of 15 of these pregnancies. This analysis generated 
guidelines for clinical practice. It is recommended that practitioners: i) remind 
couples of the long-term consequences of continuing a high risk pregnancy, ii) 
ensure couples understand the information provided, iii) collaborate closely with 
other professionals involved in the couple's prenatal care, iv) prepare couples for 
the procedural aspects of prenatal diagnosis and a possible termination of 
pregnancy, v) allow time for in-depth pre-test counselling, vi) explain the rationale 
for only making prenatal diagnosis available subject to conditions, whilst allowing 
for human ambivalence and acknowledging that these "conditions" cannot be 
enforced, vii) monitor the whole clinical process to ensure that it works "smoothly", 
viii) recommend couples do not disclose the result of the prenatal test to protect the 
confidentiality and autonomy of the future "high-risk" child, and ix) offer on-going 
contact and support. 
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INTRODUCTION Huntingtonǯs Disease (HD), caused by an expanded CAG repeat sequence in exon 1 of 
the HTT gene1, is a severe, inherited neurodegenerative condition that results in a 
progressive decline in motor function and cognitive ability together with a 
disturbance of affect. The non-motor aspects are often the more disabling for a 
patient and their family or carers.2-4 HD is inherited in an autosomal dominant 
manner and there are a number of reproductive options for couples at risk of 
transmitting HD: prenatal diagnosis (PND) using chorionic villus sampling or 
amniocentesis, preimplantation genetic diagnosis, use of donor gametes or embryo, 
adoption, proceeding to have children while aware of the risks or deciding to remain 
childless. Non-invasive prenatal diagnosis is also technically possible for some 
couples although not routinely available in the UK at the time of writing.5  
The two main types of PND are direct testing and exclusion testing.6 Direct 
testing involves testing the fetus for the presence or absence of the pathogenic HD 
variant and gives an accurate result. Exclusion testing uses linkage to test the fetus 
for the at-risk grandparental haplotype. If the haplotype is absent (i.e. excluded) then 
the fetus is known to be at low risk of HD whereas presence of that haplotype 
indicates the fetus is at the same risk as the at-risk parent. Exclusion testing is chosen 
when the at-risk parent wishes their own status to remain undetermined yet does 
not wish to have a child at risk of HD. The principal disadvantage of exclusion testing 
is that the positive predictive value of the test is only 50% so that, if a pregnancy is 
terminated on this basis, it is as likely to be unaffected as affected. 
  
One of the most ethically complex issues surrounding PND for HD is the 
potential for high-risk pregnancies to be continued to term.5,7 Current international 
guidelines clearly state that PND is not indicated for couples who would be 
committed to completing the pregnancy in the event that the fetus is found to be at a 
high risk8, although recognising that the decisions made by couples before the test 
result are somewhat hypothetical. The National Society of Genetic Counsellors argues 
on those grounds that testing should therefore not be denied a couple, even if they 
think that they would continue a pregnancy after an 'increased chance' result.9 This 
scenario would result in the child having been tested presymptomatically, thereby 
pre-empting his or her right to make an informed, autonomous decision with regards 
to predictive testing as a mature adult. Several studies have identified a small but 
significant proportion of tested, high-risk pregnancies that are continued. However, 
limited information is available on the circumstances surrounding such 'decisions to 
continue'.10-15 There is also some limited information about families affected by one 
of the spinocerebellar ataxias. In brief, eight of 28 Cuban couples continued a high 
risk SCA2 pregnancy16 and two of twelve Yakut couples continued high risk SCA1 
pregnancies.  17  
The UK Huntingtonǯs Disease Predictive Testing Consortium (HDPTC) was 
created in 1989 and collates anonymous data on predictive and prenatal testing for 
HD across the UK. The HDPTC identified that 21 of 202 high-risk pregnancies were 
continued18. In this qualitative study health professionals reviewed the case notes of 
15 of these pregnancies, with the aim to explore the circumstances surrounding 
around their continuation and identify factors that may inform future counselling for 
couples at risk of HD.  
  
METHODS 
Study Design 
HDPTC records were reviewed to identify cases from 1988 to 2015 where high risk 
pregnancies had been continued and where the case notes could be examined. Study 
design was discussed by the HDPTC and retrospective case note review chosen as the 
optimum method for this exploratory study as it would maximise the learning from 
the limited number of cases available. Retrospective case note review is an 
established method for conducting research in the healthcare setting when the aim 
is to generate a comprehensive understanding of a complex issue or phenomenon.19 
Neither review by a Research Ethics Committee nor patient consent to the 
publication of our findings was sought. Research Ethics Committee review is not 
required for a retrospective review of case notes. It would have been impossible to 
obtain patient consent and we have fully protected the privacy of the patients and 
families by removing all identifying information; the clinicians submitting data were 
acutely alert to the importance of maintaining anonymity. As the case histories have 
come from two decades and across the UK, it is most unlikely that patient identities 
could be inferred.  
Data Collection 
Semi-structured questionnaires for data collection were completed by clinicians 
from the respective genetics centres. The questionnaire was developed following 
preliminary review of two cases, peer review, and presentation to members of the 
HDPTC (Appendix 1). It captured demographic and quantitative data and included 
free text sections to allow qualitative interpretation of each case history by the 
reviewing clinician. Two lists of adjectives that could represent a couple's 
  
relationship and style of decision-making were derived through a discussion among 
genetics health professionals. Clinicians involved in each case were then asked to 
select words that represented their assessment of the couple. This design encouraged 
a focus on the research question whilst allowing flexibility to expand; this Ǯboundary settingǯ is particularly important for case note reviews.19  
 Genetics centres with cases were sent an invitation letter and questionnaire 
to complete. The letter outlined the purpose of the study and requested data 
collection by a clinician who had had direct contact with the case wherever possible 
(Appendix 2). This approach was chosen as it would collate information provided by 
clinicians who knew the individuals involved and had expertise in this disease.20   
Data Analysis 
The demographic and quantitative data were recorded and thematic analysis was 
used to interpret the answers to the open questions.21 This involved thorough 
reading of the questionnaires, recognition of emergent patterns, and generation of 
common themes. This allowed the identification of features shared between the 
cases, despite the notes having been written at different times, by different clinicians, 
about different couples.  
RESULTS 
Fifteen questionnaires were returned from ten genetics centres. This represents 71% 
of the cases recorded by the HDPTC where a pregnancy at high risk had been 
continued. The majority of questionnaires were completed with only minimal 
omission of information, when it was not available in the clinical notes. Thematic 
analysis of the qualitative data from the free text sections, in combination with 
quantifiable information, identified the following themes: 
  
Absence of defining characteristics 
There seemed to be no single defining characteristic shared by all couples that might 
help identify those likely to continue a high-risk pregnancy. We were unable to 
compare these 15 cases with the much larger number of cases where the pregnancy 
was terminated but we could discern no trend in demographic characteristics (Table 
1). In eleven cases the at-risk parent was female and in four cases they were male, 
with the higher proportion of female carriers expected as it reflects that more women 
than men at risk of HD seek predictive and prenatal testing. Nine had not had 
predictive genetic testing and were at 50% risk of HD, and five had received a high-
risk positive predictive test result. One parent was displaying symptoms of HD. The 
age range of the at-risk parent was from 19-41 years, with a mean age of 29 years. In 
addition, the couples had varying religious beliefs and different reproductive 
histories. Some of the pregnancies had been planned, but others had not. The couples 
varied in how long they had known about HD in the family and whether they had 
received genetic counselling prior to the pregnancy. All but one of the pregnancies 
were in their first trimester at the point of referral, which is usually the case for 
couples considering PND. None of the couples requested predictive testing in 
pregnancy prior to PND, a situation associated with additional challenges.22 
Couples were generally close and supportive 
When asked to select the adjectives that best represented each couple's relationship, 
the clinicians most frequently selected Ǯlong-termǯ, Ǯcommittedǯ and Ǯlovingǯ (Table 2). 
Data from the free text supported this view with couples described as Ǯmutually supportiveǯ, Ǯinsightfulǯ, and Ǯin complete agreement with how to proceedǯ. There 
were two exceptions; in one case the couple had separated and they differed on 
  
whether they would continue the pregnancy if the result was high risk. Indeed, one 
partner requested a social termination of pregnancy (TOP). In the other, one partner 
had advanced symptoms of HD contributing to serious social issues that worsened 
following the pregnancy, as the disease progressed. For eleven of the couples, data 
were available that showed how long the couples had been in a relationship. Only one 
couple (described as "completely devoted") had been together for less than two 
years.  
Decision-making was informed yet confused 
Each couple had contact with the clinical genetics team during the pregnancy and 
prior to the PND procedure (Table 3). These contacts were often numerous, although 
for one couple the only contact during the pregnancy was by telephone. Most couples 
were thought to be well informed about the ethical complexities of PND for HD and 
had expressed explicitly that they would have a TOP in the event of a high-risk result. 
However, free text data emphasised the difficulties that couples faced in their 
decision-making once the high-risk result was known. Words representing the couplesǯ decision-making most commonly included Ǯconfusedǯ and Ǯpressureǯ (Table 
2). In individual cases, factors were identified that added to the difficulties in 
decision-making, including: a reduced penetrance allele, religious beliefs, discordant 
views between partners, the inability to face TOP 'for real', increasing attachment to 
the pregnancy, altered perception of the severity of HD, history of miscarriages and 
increasing optimism for the future. 
Doubt caused by external influences 
There were a number of reports of the couplesǯ decision-making being influenced by 
external factors. In particular, these included interactions with non-genetics health 
  
professionals, such as those from fetal medicine or gynaecology departments at the 
time of chorionic villus sampling (CVS) and TOP. Non-specialist (non-genetics) staff 
had misunderstandings about the test results, particularly for exclusion testing, and 
the ethical acceptability of TOP for an adult onset condition was questioned. Thus, 
one mother was reported as stating that “a [professional] had told her she would not 
be allowed to see (the) baby or get photographs" although the notes clearly 
documented that the process had been explained and extensive counselling provided. 
Another couple recalled that staff on a gynaecology ward had described the risk to 
their fetus as "only a risk"; this changed the couple's perception of the situation. 
Couples were said to have been influenced by relatives, who had often become aware 
of pregnancies at the end of the first trimester. This included relatives encouraging 
and reassuring one couple to continue the pregnancy. Another couple could not face 
a TOP whilst already experiencing the grief associated with the advancing disease of 
an affected parent. A further couple reflected on the at-risk parentǯs own right to life, 
which had been honoured by their parents despite the risk of HD. 
Delays to expected time scales  
It is noteworthy that one third of the 15 couples had experienced unexpected delays 
at some point during the PND process, although we cannot compare this figure with 
that for the pregnancies that were terminated. Thus, one couple required a repeat 
CVS due to inadequate sample at the first attempt, so that they could only access TOP 
by a medical not surgical procedure. Another couple experienced a delay of five days 
in receiving the results of the PND. A delay in scheduling the TOP procedure in one 
case meant the TOP could not occur within a timescale acceptable to their religious 
beliefs. Further delays occurred when couples considered requesting a direct test 
  
following a high-risk exclusion test result. The free text data highlighted how these 
delays may have influenced the decision to continue these pregnancies despite the 
high-risk result. 
Lack of follow up 
About half the couples cut ties with the genetics service despite multiple previous 
contacts and a seemingly good relationship (Table 4). Many couples did not even 
inform the department of their decision to continue the pregnancy. One couple "left 
the (TOP) ward after discussion with medical staff via (the) fire escape: (they) did not 
tell staff they were leaving"; another couple chose not to receive the results of a direct 
test that followed an exclusion test. In general, follow up was limited by couplesǯ 
decisions following PND.  
Telling the Children 
The clinical notes generally suggested that couples did not plan to tell their children 
of their genetic status; however, they predicted that the test results would most likely 
become known. Subsequent predictive testing of the at-risk parent was sought in two 
cases but performed in only one case, in which the parent recalled the prenatal 
exclusion test results as "inconclusive" despite having received a positive test result. 
In one case, serious social difficulties developed and it was unclear whether the child 
had been told their prenatal test result. 
DISCUSSION 
This is the first study (to our knowledge) to review the clinical case notes of couples 
undergoing PND for HD and continuing with a high-risk pregnancy. This has 
identified a number of important considerations for how to deliver optimal care and 
support for couples considering PND for HD. Although these measures are already 
  
widely practised by genetics centres, we hope that proposing them as guidelines 
might reduce the frequency of predictive information being generated on newborn 
infants at risk of HD, which occurs following ~10% of those prenatal diagnoses giving 
a high-risk result in the UK.  
Offer in-depth counselling to all couples 
The results demonstrate the absence of particular characteristics that could alert 
genetics professionals to those couples that might continue a high-risk pregnancy. 
For instance, it might be expected that these couples would be less likely to have 
received pre-conception genetic counselling, which is recognised as important to 
allow couples time to consider all available options, make informed decisions, and 
avoid simultaneous predictive and prenatal testing.8 However, eleven couples did 
have contact with genetics services prior to the pregnancy. A larger proportion of 
unplanned pregnancies might also be expected in this cohort,5 yet around half of the 
pregnancies were planned. Similarly, Ǯyoungǯ couples have been predicted to be more 
likely to continue a high-risk pregnancy due to increased uncertainty,22 but there was 
a wide age range in our data set. Interestingly, a recent study in France found that 
reproductive decisions in HD are made afresh with each pregnancy, which reflects 
our findings.24 A conflict-prone or troubled relationship might also be anticipated 
more often in these couples but, contrary to this, thirteen of the couplesǯ relationships 
were perceived to be close and supportive. Decruyenaere et al12 also found 
agreement between spouses in decision-making for reproductive choice in HD, and 
Bouchghoul et al.24 found no significant impact of the outcome of PND for HD on couplesǯ relationship status over time.  
 Prenatal testing for HD requires high quality counselling by a fully informed 
  
professional.8,12 We were unable to recognise any clear indicators to predict which 
couples would continue a high-risk pregnancy. This suggests the need for 
professionals to emphasise the complex and long-term ethical consequences of 
continuing a pregnancy at high risk to every couple considering prenatal diagnosis, 
whether before or during an ongoing pregnancy. However, the case studies reported 
here do not indicate any lack of such information or counselling support. It is likely 
that couples will change their minds about a TOP in the face of a high-risk result 
despite the very best genetic counselling practice. We must accept that humans 
experience ambivalence in difficult circumstances and we should resist any 
inclination to blame either the patients or the professionals involved. 
Evaluate couples’ comprehension 
The couplesǯ decision-making was described by the clinicians as informed yet 
confused. Studies demonstrate that couples have great difficulty in grasping certain 
concepts during prenatal counselling for HD, particularly relating to exclusion 
testing, with up to 90% of couples requiring repeated explanation.23,25 This study 
found that comprehensive information had been provided, although retrospective 
assessment of the couplesǯ understanding and information retention is not available. 
Irrespective of the patients' educational backgrounds, it is crucial that genetics 
professionals ensure that couples understand the information provided and that the 
issue of TOP is addressed directly.25 We therefore suggest prenatal counselling 
should routinely include strategies actively to evaluate couplesǯ understandings, 
particularly around exclusion testing, the possibility of Ǯgrey areaǯ results and the 
ethical implications of continuing a likely affected pregnancy. Detailed technical 
information is perhaps less important than helping couples to appreciate the 
  
potential implications of each of the possible test results and pregnancy outcomes for 
their own unique set of personal circumstances. The greater attention sometimes 
paid in prenatal genetic counselling to the provision of information as opposed to the 
salient counselling issues has been noted before.26 Highlighting and rehearsing 
information recall under the immense pressure couples will experience following the 
CVS result may also be beneficial. 
Educate other healthcare providers, especially those involved in managing a 
pregnancy  
Feelings of confusion and uncertainty during the decision-making process in PND for 
HD have been recognised before.23 Conflicting messages from sources external to the 
genetics services contributed to the confusion in the making of decisions. Some 
couples were apparently influenced by the opinions of their relatives, who had often 
become aware of the ongoing pregnancy by the end of the first trimester and 
encouraged couples to continue. The impact of relatives' views on reproductive 
choice in families with HD has been recognised.27 However, more numerous and 
notable were the instances of confusion triggered by information from non-genetics 
health professionals. This was usually from staff in fetal medicine or gynaecology 
units at the time of the CVS or TOP. 
 It is critically important that health professionals from all disciplines involved 
in reproductive care provide accurate information and clear advice that is consistent 
with the input provided in genetic counselling.28 However, in the cases we report, 
misunderstandings and mixed messages about the meaning of results seem to have 
arisen among the non-genetics professionals, particularly about exclusion testing and 
the ethics of TOP for an adult onset condition. At a time when couples often form a 
  
stronger attachment to their pregnancy, and when their decision-making is already 
highly pressured, couples may have been particularly influenced by these messages 
conflicting with their previous decisions. The mixed messages to which they were 
exposed may have been pivotal in how these couples chose to proceed.  
We wish to highlight the importance of the education of non-genetics health 
professionals about the unique features of PND for HD. Effective multidisciplinary 
team working and communication with the couple's primary care team and 
midwife/obstetrician should be maintained to provide the maximum support. 
Standard good practice should include copying correspondence to all relevant health 
professionals. This unique scenario may also benefit from a face-to-face discussion 
between the midwife, obstetrician and genetic counsellor. The prenatal genetic 
counselling process might also forewarn couples about the potential for 
misunderstanding by other professionals and suggest taking genetics summary 
letters to hospital appointments.  
Prepare couples for the reality of the process of PND and termination of 
pregnancy 
Part of preparing couples for PND is establishing a defined timeline of events, often 
including set dates for an ultrasound dating scan, the CVS procedure, and the delivery 
of results. It is also known that waiting for the results of PND is difficult and 
distressing,24,29 and that support with the practical arrangements for a TOP following 
unfavourable results is very important.23 A number of couples in this cohort 
experienced delays during the PND process, which were thought to have contributed 
to their decisions to continue their pregnancies. CVS testing is usually conducted at 
around twelve weeks gestation, a time when couples often have their first ultrasound 
  
scan, develop a stronger bond with the pregnancy and inform family members about 
it.30 Delays of even a few days may dramatically alter how couples feel towards the 
pregnancy, with evidence suggesting couples might suddenly feel a new level of 
attachment as bonding increases with gestation.31 Indeed, seeing the ultrasound 
image of the fetus has been recorded as the reason one couple chose to continue a 
high risk pregnancy.32 For several couples, the procedural delays, added to an already 
pressured decision-making process, may have disrupted their rehearsed schedule of 
events and meant that they found it even harder to bear the prospect of terminating 
an otherwise wanted pregnancy. Whilst there is an inevitable progression to 
pregnancy, efforts can be made to ensure couples are prepared for the reality of the 
procedure, the possibility of delays and the emergence of a new level of attachment 
to the pregnancy. There is a paucity of literature evaluating coping mechanisms in 
women undergoing PND,33 however coping strategies for this group can be discussed 
and might include (i) a decision as to whether to view the ultrasound image at CVS, 
(ii) consideration of whether they disclose details of their pregnancy to relatives, and 
(iii) forewarning genetics laboratories and fetal medicine teams of the upcoming PND 
test. Every effort should be made to avoid delays. Another important area is the 
continued education for genetics professionals on the principles of caring for women 
undergoing prenatal procedures.29 Genetics professionals are well versed in the 
ethical and genetic counselling aspects of PND for HD. However, while their 
experience of the procedural aspects of PND and their impact on couples may be 
limited, this seems crucial in the preparation of couples who plan to proceed with 
PND and, perhaps, a TOP. 
Support complex decision-making 
  
The results describe the range of factors that were identified as compounding the 
difficulties of couples' decision-making. Notably, one couple received a high-risk 
result on a prenatal exclusion test. They opted for direct testing but then chose not to 
receive the result. This could represent the avoidance of possible Ǯdouble bad newsǯ 
where the fetus and at-risk parent are diagnosed simultaneously.25,34  
 We were unable to capture enough detail in this review to evaluate each factor 
individually. Cumulatively, however, these case histories highlight the complexity of 
the couplesǯ decision-making. Additional influences on decision-making for couples 
who have continued a high risk pregnancy include outcomes from previous PND,24 
doubting the at-risk parentǯs predictive test result,23 TOP for a pregnancy at 50% risk 
in the case of exclusion testing,10 ambivalence, and cognitive decline or emotional 
lability in the at-risk parent as a result of HD.32 There is also the suggestion that, when 
couples discover their fetus has a smaller CAG repeat size than the affected parent, 
albeit still pathogenic, this may nurture their sense of hope for the future.14 
Increasing access to social media and the internet, and the introduction of new 
prenatal testing procedures such as non-invasive prenatal diagnosis, may further 
complicate reproductive decision-making.5,28 New technologies may also exacerbate 
the so-called Ǯtechnological imperativeǯ facing couples.12,23 The range of factors 
influencing couplesǯ reproductive decision-making after genetic counselling has been 
reviewed.28 Genetics professionals must allow time, including additional clinic 
appointments if needed, for in-depth, pre-test counselling.  
Empower couples to access support in the long-term 
There was limited information in the clinic notes about the ongoing impact of each 
couple's decision on the child and the family as a whole. Indeed, many couples appear 
  
to have consciously disengaged from genetics services, despite regular prior contact 
and a seemingly good relationship. We speculate they may have felt apprehensive 
about disclosing their decision as it was contrary to the previously expressed and 
agreed course of action. While current international guidelines recommend that 
access to PND for those at risk of transmitting HD be conditional upon agreement to 
terminate a high-risk pregnancy, these guidelines do not overrule a couple's - or the 
woman's - entitlement to change their mind after receiving the test result.5,7,8,9  
 The high-risk result for each of these pregnancies is known by at least the 
couple and a number of health professionals, thus the future childǯs right to 
confidentiality over his or her genetic status has been breached, as has, most 
probably, their ability to make an informed, autonomous decision with regards to 
predictive testing as a mature adult. To limit the extent of this breach, we recommend 
that couples are counselled to not disclose the results of the PND to relatives or 
friends. The likely burden on couples of carrying this information in isolation 
presents another compelling reason to empower couples to access support in the 
long-term. 
SUMMARY AND CONCLUSION 
Genetic counselling for PND in HD is a challenging balance between offering non-
directive support to couples in making an informed choice, versus the offer of PND 
being presented and understood as, in effect, conditional upon an agreement to 
terminate a high-risk pregnancy. Achieving an understanding with couples that 
acknowledges the rationale for PND whilst also conveying impartiality and a 
recognition of human ambivalence seems key to maintaining long-term contact. 
Genetics professionals invest much time and effort counselling couples in this 
  
scenario and are skilled in supporting families at risk of HD. Given the abrupt 
termination of contact by couples when they continue their high-risk pregnancies, 
the professionals involved may feel that they failed in their counselling and they 
could be left with concerns about how the situation might evolve for the families. This 
remains an important area for further research.  
Further studies investigating the long-term impact of continued high-risk 
pregnancies on families are crucial if genetics professionals are to learn how best to 
support families both at the time of PND and as the situation evolves over time. There 
is very limited literature addressing this issue, presumably as this situation arises 
infrequently and there is a lack of follow up information. Recently Bouchghoul et al24 
examined whether children are informed about their genetic status following PND 
for HD and report one case of a continued pregnancy at high risk. The carrier mother 
in this instance had not disclosed the result to her then 9 year-old child; the usual age 
of disclosure for those children with a negative HD test prenatally was 10-18 years. 
Psychological support following PND for HD, especially following a bad news result, 
is imperative24 and recommendations for predictive testing in HD reiterate the 
importance of follow up.8 Therefore, until there is specific evidence for how best to 
support couples that have continued a high-risk pregnancy, we suggest genetic 
services make every effort to continue to offer on-going contact. Couples considering 
PND are routinely signposted to additional support options, such as the Huntington 
Disease Association, and these may serve as alternatives for couples that decline on-
going support. 
Summary of guidelines for clinical practice 
i. Before the diagnostic procedure, remind every couple of the complex and long-term 
  
ethical consequences of continuing a pregnancy at high risk of HD. 
ii. Help couples to understand the information provided, evaluate their understanding 
as part of the counselling process, and rehearse their recall in the scenario of a high-
risk result. 
iii. Educate other health professionals about the exceptional circumstances of PND for 
HD and ensure good multidisciplinary team working. 
iv. Prepare couples for the reality of the PND and TOP procedures; discuss and rehearse 
coping strategies. 
v. Allow sufficient time for in-depth pre-test counselling, given the complexity of these 
decisions. 
vi. Explain the rationale for the offer of PND being made conditional upon a 
commitment to terminate the pregnancy if the test gives a high-risk result, whilst 
allowing for human ambivalence.   
vii.  Monitor the whole process of diagnostic procedure, laboratory analysis, return of 
results and organisation of TOP to ensure it works without delays or confusions. 
viii.  Recommend that couples do not disclose the result of the prenatal test, so as to 
protect the confidentiality and autonomy of the future child. 
ix. Make every effort to offer on-going contact and support to couples. 
Strengths and Limitations 
A strength of this study is that data were obtained from the case-notes of a substantial 
proportion of all UK recorded cases where pregnancies known to be at high risk of 
HD have been continued. Furthermore, the clinicians who completed the 
questionnaires were all genetics professionals with a specialist interest in HD who 
were, therefore, well placed to provide relevant and insightful responses. Conversely, 
  
the fact that the professionals were drawn from different locations may be seen as a 
limitation of the study. The retrospective design, the necessity for potentially 
identifying data to be omitted, and the lack of detail in some case notes were further 
limitations. Our inability to compare these 15 cases with those where increased risk 
pregnancies were terminated prevents us from making systematic comparisons 
between those cases where pregnancies were and were not terminated.  Finally, the 
lack of follow up contact with couples results in the outcomes for many couples 
remaining unclear. Many of these limitations would be mitigated if data collection in 
the future is prospective; this would entail collecting data on all pregnancies subject 
to prenatal testing for HD.  
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